Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04086316
Other study ID # CycleDepression
Secondary ID
Status Completed
Phase
First received
Last updated
Start date January 15, 2020
Est. completion date December 30, 2022

Study information

Verified date February 2023
Source Freie Universität Berlin
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Background: Major changes in female sex hormone concentrations influence the development of depressive symptoms in women. This hypothesis has been thoroughly investigated with regard to the menopause, the postpartal phase and also premenstrual dysphoric disorder. However, much less is known regarding the impact of female sex hormone fluctuations on depression during the regular menstrual cycle. There are indications that during the luteal phase, women might be more vulnerable to the development of depressive symptoms, while during the follicular phase and at ovulation, hormone concentrations might present a protective factor against depressive symptomatology. Subjective stress could mediate the relationship between depressive symptom development and the menstrual cycle phases. The complex interaction between sex hormones and psychological symptoms in the course of menstrual cycle phases is still understudied. Method: 74 women (37 with and 37 without current depressive episode), will take part in a smartphone-based ambulatory assessment. Women will provide daily ratings of depressive symptoms and perceived stress for a period of one menstrual cycle (approx. 26-30 days). Three menstrual cycle phases will be assessed - the follicular phase, ovulation and the luteal phase. An ambulatory assessment will be used for these daily assessments. To assess the menstrual cycle phase participants will use ovulation tests on five days in the late follicular phase. The following research questions will be investigated: Research question 1: Do depressive symptoms (number and severity) change in the course of the menstrual cycle within the two groups? Research question 2: Which depressive symptoms are particularly sensitive to changes in the course of the menstrual cycle phases? Research question 3: Does the subjective stress change in the course of the menstrual cycle within the two groups? Research question 4: Are there differences between depressive and healthy women in terms of changes in depressive symptoms and subjective stress experience? Implications: The aim of the study is to investigate women-specific psychobiological factors influencing depression. Therefore, fluctuations in depressive symptoms and subjective stress experience will be investigated as a function of the respective menstrual cycle phases. The identification of cycle phases associated with increased or reduced vulnerability to depressive symptoms will support the development of women-specific prevention and treatment programs.


Recruitment information / eligibility

Status Completed
Enrollment 77
Est. completion date December 30, 2022
Est. primary completion date April 15, 2021
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 18 Years to 45 Years
Eligibility For participants with major depressive episode: Inclusion criteria: - female sex - current diagnosis of a major depression episode - minimum age of 18 years - regular menstrual cycle. Exclusion criteria: - Pregnancy less than one year ago; - women who are breastfeeding; - bipolar disorder; - acute suicidal tendencies; - schizophrenic disorders (F20-29); - substance use disorders - psychotropic drugs in the last six months; - chronic somatic diseases. For participants without major depressive episode: Inclusion criteria: - female sex; - minimum age of 18 years; - regular menstrual cycle. Exclusion criteria: - current or lifetime mental disorder; - pregnancy less than one year ago; - women who are breastfeeding; - psychotropic drugs in the last six months; - chronic somatic diseases.

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
Germany Freie Universität Berlin Berlin

Sponsors (1)

Lead Sponsor Collaborator
Freie Universität Berlin

Country where clinical trial is conducted

Germany, 

Outcome

Type Measure Description Time frame Safety issue
Primary Changes in Depressive Symptoms between the menstrual cycle phases Depressive Symptoms will be measured with the Patient Health Questionnaire (PHQ-9), which will be adapted for the ambulatory assessment use (e.g. changing "in the last two weeks" to "right now"). Depressive Symptoms will be assessed daily with an ambulatory assessment for the duration of one menstrual cycle (approx. 28 days).
Primary Changes in subjective stress (self report) between the menstrual cycle phases Stress Symptoms will be measured with the short Version of the Perceived Stress Scale (PSS-4), which will be adapted for the ambulatory assessment use (e.g. changing "in the last two weeks" to "right now"). Subjective stress will be assessed daily with an ambulatory assessment for the duration of one menstrual cycle (approx. 28 days).
Secondary Differences between women with and without a Major depressive Episode Differences between women with and without a Major depressive Episode (measured with the SCID-CV) Depressive Symptoms will be assessed daily with an ambulatory assessment for the duration of one menstrual cycle (approx. 28 days).
Secondary Differences between women with and without a Major depressive Episode Differences between women with and without a Major depressive Episode (measured with the SCID-CV) Subjective stress will be assessed daily with an ambulatory assessment for the duration of one menstrual cycle (approx. 28 days).
See also
  Status Clinical Trial Phase
Completed NCT03256162 - Ketamine as an Adjunctive Therapy for Major Depression Phase 1
Completed NCT01944293 - Ketamine for Suicidality in Bipolar Depression Phase 1/Phase 2
Recruiting NCT01441505 - A Study of Ketamine as an Antidepressant Phase 2
Active, not recruiting NCT03487926 - Microglial Activation in Inflammatory Bowel Disease
Recruiting NCT04939649 - Ketamine as an Adjunctive Therapy for Major Depression (2) Phase 3
Recruiting NCT05028738 - Patient-oriented Randomized Pragmatic Feasibility Trial With rTMS in Depression and Anxiety N/A
Recruiting NCT03646058 - Add-on Buprenorphine at Analgesic Doses for the Treatment of Severe Suicidal Ideas During a Major Depressive Episode Phase 3
Not yet recruiting NCT06117397 - A Text Messaging Intervention to Reduce Perinatal Depression Risk N/A
Completed NCT03735576 - Cognitive Behavioural Therapy for the Treatment of Late Life Depression N/A
Recruiting NCT04999553 - Left vs. Right Non-Inferiority Trial N/A
Completed NCT03716869 - Universal vs. Targeted School Screening for Adolescent Major Depressive Disorder N/A
Recruiting NCT02824081 - Neuroinflammation, Serotonin, Impulsivity and Suicide N/A
Terminated NCT01099592 - Antidepressants to Promote Recovery of Cardiac Patients Suffering From Depression Phase 4
Completed NCT03752853 - Stress Systems and Psychotherapy in Depression N/A
Recruiting NCT04480918 - University of Iowa Interventional Psychiatry Service Patient Registry
Recruiting NCT04130958 - Circuit-Based Approach to Suicide: Biomarkers, Predictors, and Novel Therapeutics N/A
Completed NCT03190772 - The Role of Expectations in the Pharmacological Treatment of Depression - An Experimental Investigation N/A
Recruiting NCT04832750 - Depression-Reduction by Accelerated Personalized NeuroModulation and Its Effects on Sleep
Terminated NCT02839798 - NeoSync TMS Treatment for Bipolar I Depression Phase 2
Completed NCT00852592 - Light Therapy for Bipolar Disorder. Efficacy of Light Therapy for Bipolar Depression: A Randomized Controlled Trial Phase 3